RGTI
Rigetti Computing
-- 17.0800 TSLA
Tesla
-- 431.660 NVDA
NVIDIA
-- 137.010 LAES
SEALSQ Corp
-- 9.080 PLTR
Palantir
-- 79.080 
NEWS
Newly Published Review Highlights the Pivotal Role of Daxor’s Blood Volume Analysis Technology in Advancing Cardiorenal Syndrome Management
Daxor (Nasdaq: DXR) announces a pivotal review published in Cardiorenal Medicine highlighting the important role of Blood Volume Analysis (BVA) in managing cardiorenal syndrome (CRS). The review, authored by expert contributors, emphasizes BVA's significance in enhancing the precision of diuretic and red cell therapies, leading to improved patient care and outcomes. Key findings include:
BVA's 98% accuracy in measuring total blood and red blood cell volumes
BVA's potential to optimize personalized therapy for CRS patients
Projected growth of CRS patient population to 47 million by 2030
Daxor's CEO, Michael Feldschuh, emphasizes BVA technology's potential to improve outcomes while reducing care duration and costs in CRS management
Daxor (Nasdaq: DXR) announces a pivotal review published in Cardiorenal Medicine highlighting the important role of Blood Volume Analysis (BVA) in managing cardiorenal syndrome (CRS). The review, authored by expert contributors, emphasizes BVA's significance in enhancing the precision of diuretic and red cell therapies, leading to improved patient care and outcomes. Key findings include:
BVA's 98% accuracy in measuring total blood and red blood cell volumes
BVA's potential to optimize personalized therapy for CRS patients
Projected growth of CRS patient population to 47 million by 2030
Daxor's CEO, Michael Feldschuh, emphasizes BVA technology's potential to improve outcomes while reducing care duration and costs in CRS management
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment